Australia is facing an obesity crisis of unprecedented proportions. According to the Australian Institute of Health and Welfare, approximately two-thirds of Australian adults are overweight or obese, contributing to a cascade of chronic health conditions including type 2 diabetes, cardiovascular disease, and certain cancers. Against this backdrop, weight loss peptides have emerged as one of the most promising areas of metabolic research, offering novel mechanisms for addressing excess body fat and metabolic dysfunction.
Unlike traditional weight loss approaches that rely primarily on caloric restriction and increased physical activity, weight loss peptides target specific biological pathways involved in appetite regulation, fat metabolism, and energy homeostasis. This targeted approach has yielded remarkable results in clinical trials, with some peptides demonstrating weight loss outcomes that rival bariatric surgery — without the surgical risks.
In this comprehensive guide, we examine four of the most significant weight loss peptides available for research in Australia: AOD-9604, Cagrilintide, Tirzepatide, and Retatrutide. Each represents a different approach to metabolic modulation, and together they illustrate the extraordinary potential of peptide-based weight management research.
Weight regulation is controlled by an intricate network of hormones, neuropeptides, and signalling pathways that communicate between the gut, brain, adipose tissue, and other organs. Key players in this network include leptin (the satiety hormone), ghrelin (the hunger hormone), insulin, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and amylin.
Weight loss peptides work by modulating one or more of these signalling pathways. Some, like GLP-1 receptor agonists, reduce appetite by mimicking satiety signals. Others, like AOD-9604, directly influence fat metabolism without affecting appetite. The most advanced compounds, like Tirzepatide and Retatrutide, target multiple pathways simultaneously — an approach known as poly-agonism that has produced unprecedented weight loss results in clinical trials.
AOD-9604 (10mg) holds a special place in Australian peptide history — it was developed right here in Australia at Monash University in Melbourne. This modified fragment of human growth hormone (specifically, amino acids 177-191 of the GH molecule, with a tyrosine addition) was designed to capture GH’s fat-burning properties without its growth-promoting or diabetogenic effects.
AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) through mechanisms that are distinct from full-length growth hormone. Research published in Obesity Research demonstrated that AOD-9604 activates beta-3 adrenergic receptors on adipocytes, triggering the release of stored fatty acids for energy use. Crucially, AOD-9604 does not affect blood glucose levels or stimulate IGF-1 production, making it a cleaner metabolic tool than full-length GH.
The Australian origins of AOD-9604 research have produced a wealth of data. Early studies at Monash University demonstrated that the peptide could reduce body fat in obese mice without affecting lean mass, food intake, or blood glucose. Subsequent human clinical trials showed modest but statistically significant reductions in body weight, with the peptide demonstrating an excellent safety profile.
AOD-9604 has also shown promise in cartilage repair research. The TGA has granted AOD-9604 Generally Recognised As Safe (GRAS) status for use in food products, reflecting its favourable safety profile. Studies have demonstrated that AOD-9604 can stimulate proteoglycan and collagen production in cartilage cells, opening up potential applications in osteoarthritis research — a condition that affects over 2.2 million Australians.
Cagrilintide (5mg) represents a significant advancement in amylin-based weight loss research. This long-acting amylin analogue was developed to address the limitations of earlier amylin-based therapies, offering improved pharmacokinetics and enhanced efficacy for metabolic research.
Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. It plays a crucial role in glucose homeostasis and appetite regulation by slowing gastric emptying, suppressing glucagon secretion, and promoting satiety through central nervous system mechanisms. Cagrilintide mimics and amplifies these effects, with a modified structure that extends its duration of action and enhances its receptor binding affinity.
Research published in The Lancet has shown that Cagrilintide activates amylin receptors in the area postrema and nucleus tractus solitarius — brain regions critical for appetite regulation — producing sustained reductions in food intake and body weight.
Phase 2 clinical trials of Cagrilintide demonstrated dose-dependent weight loss of up to 10.8% over 26 weeks in participants with overweight or obesity. These results positioned Cagrilintide as one of the most effective single-agent amylin analogues ever tested. The peptide was generally well-tolerated, with gastrointestinal side effects (primarily nausea) being the most commonly reported adverse events.
Perhaps most excitingly, Cagrilintide is being investigated in combination with semaglutide (a GLP-1 receptor agonist) in the CagriSema programme. Early results from this combination approach have shown weight loss exceeding 15% — approaching the efficacy of bariatric surgery. This combination strategy exemplifies the potential of targeting multiple metabolic pathways simultaneously.
Tirzepatide (10mg) has been described as a game-changer in metabolic research, and the data supports this characterisation. As the first dual GIP/GLP-1 receptor agonist, Tirzepatide represents a fundamentally new approach to weight management that has produced unprecedented results in clinical trials.
Tirzepatide simultaneously activates two incretin receptors: the GLP-1 receptor and the GIP receptor. GLP-1 receptor activation reduces appetite, slows gastric emptying, and improves insulin sensitivity. GIP receptor activation enhances insulin secretion, improves fat metabolism, and may have direct effects on adipose tissue. The combination of these two mechanisms produces synergistic effects that exceed what either pathway can achieve alone.
Research published in the New England Journal of Medicine has elucidated the molecular basis for Tirzepatide’s superior efficacy, demonstrating that dual receptor activation produces more robust improvements in glycaemic control, insulin sensitivity, and body weight than GLP-1 receptor agonism alone.
The SURMOUNT clinical trial programme has produced landmark results for Tirzepatide in weight management. The SURMOUNT-1 trial demonstrated that Tirzepatide at the highest dose (15mg weekly) produced an average weight loss of 22.5% over 72 weeks in participants without diabetes — results that are comparable to some bariatric surgical procedures. Approximately one-third of participants achieved weight loss of 25% or more.
Beyond weight loss, Tirzepatide has shown remarkable improvements in cardiometabolic risk factors, including reductions in waist circumference, blood pressure, triglycerides, and inflammatory markers. The peptide has also demonstrated significant improvements in glycaemic control in people with type 2 diabetes, leading to its approval for diabetes treatment in multiple countries.
Retatrutide represents the cutting edge of weight loss peptide research. As the world’s first triple GIP/GLP-1/glucagon receptor agonist, Retatrutide takes the poly-agonist approach one step further than Tirzepatide by adding glucagon receptor activation to the mix.
Retatrutide activates three distinct receptors: GLP-1 (appetite suppression and insulin sensitisation), GIP (enhanced insulin secretion and fat metabolism), and glucagon (increased energy expenditure and hepatic fat reduction). The addition of glucagon receptor agonism is particularly significant because glucagon increases energy expenditure through thermogenesis and promotes hepatic fat oxidation — effects that complement the appetite-suppressing actions of GLP-1 and GIP receptor activation.
Phase 2 clinical trial results for Retatrutide, published in the New England Journal of Medicine, demonstrated truly extraordinary weight loss outcomes. At the highest dose tested (12mg weekly), participants achieved an average weight loss of 24.2% over 48 weeks — and the weight loss curves had not yet plateaued, suggesting even greater reductions with longer treatment duration.
Retatrutide has also shown remarkable effects on liver fat. In a sub-study of the phase 2 trial, participants with non-alcoholic fatty liver disease (NAFLD) experienced an average 82% reduction in liver fat content, with the majority achieving complete resolution of hepatic steatosis. Given that NAFLD affects approximately 25% of the Australian population, these findings have enormous potential implications for liver disease research.
Each weight loss peptide offers unique advantages for different research applications:
For fat metabolism research: AOD-9604 provides a clean tool for studying lipolysis and lipogenesis without confounding effects on appetite or glucose metabolism.
For amylin pathway research: Cagrilintide offers a long-acting amylin analogue ideal for investigating amylin’s role in appetite regulation and glucose homeostasis.
For dual incretin research: Tirzepatide enables investigation of the synergistic effects of simultaneous GIP and GLP-1 receptor activation.
For triple agonist research: Retatrutide provides the most comprehensive metabolic tool, allowing researchers to study the combined effects of GLP-1, GIP, and glucagon receptor activation.
Australia’s obesity epidemic has created an urgent need for effective weight management solutions. The economic burden of obesity in Australia exceeds $11 billion annually, encompassing direct healthcare costs, lost productivity, and reduced quality of life. Research institutions across the country — from the Baker Heart and Diabetes Institute in Melbourne to the Charles Perkins Centre in Sydney — are actively investigating peptide-based approaches to weight management.
The Australian research community is particularly well-positioned to advance weight loss peptide science, given the country’s strong tradition of metabolic research, world-class clinical trial infrastructure, and diverse population that enables studies across different ethnic and demographic groups.
Researchers exploring metabolic health may also find value in our growth hormone peptides, which can influence body composition through GH-mediated pathways, or our healing peptides, which may support the gastrointestinal health that is increasingly recognised as central to metabolic function.
Weight loss peptides represent a transformative development in metabolic research, offering targeted, mechanism-based approaches to one of Australia’s most pressing health challenges. From the Australian-developed AOD-9604 to the revolutionary triple agonist Retatrutide, these peptides are reshaping our understanding of weight regulation and opening new avenues for therapeutic intervention.
Whether your research focuses on fat metabolism, appetite regulation, incretin biology, or comprehensive metabolic modulation, our range of weight loss peptides provides the tools you need. Explore our complete weight loss peptide collection and advance your metabolic research today.
Australia’s leading supplier of high-purity research peptides. Committed to scientific excellence and fast, secure domestic distribution.
Research Disclaimer: All products sold by Aus Bio Peps are strictly for laboratory research and development purposes only. These products are not for human consumption, medical, or diagnostic use. Please consult the TGA guidelines regarding research chemicals.
© 2026 Aus Bio Peps. All Rights Reserved. Based in Australia.
